The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 10/12/2023 featuring funding details for Hook, Aclid, and much more. This page will be updated throughout the day to reflect any new fundings.
Hook – $3M
Hook, an AI-powered music tech platform that allows users to make legalized mixes of songs for social media, has raised $3M in Seed funding from investors that include Point72 Ventures, Waverley Capital, Three Six Zero, and Avex. Hook was founded by Gaurav Sharma in 2023.
Aclid – $3.3M
Aclid, a security and compliance automation platform for the biotech industry, has raised $3.3M in Seed funding from investors that include IA Ventures and 2048 Ventures. Aclid was founded by Kevin Flyangolts in 2021.
The AlleyWatch audience is driving progress and innovation on a global scale. There are a number of options to reach this audience of the world’s most innovative organizations and startups at scale including strategic brand placement, lead generation, and thought leadership in front of an audience that comprises the vast majority of key decision-makers in the NYC business community and beyond. Learn more about advertising to NYC Tech, at scale.
Sincera – $4.2M
Sincera, a metadata analysis and tracking platform for adtech companies, has raised $4.2M in Seed funding from investors that include NextView Ventures, AperiamVentures, LiveRamp, and The Trade Desk. Sincera was founded by Mike O’ Sullivan and Ian Meyers in 2022.
Membrane Labs – $20M
Membrane Labs, an institutional crypto trading and lending platform, has raised $20M in Series A funding from investors that include Two Sigma Ventures, Point72 Ventures, GSR, Framework Ventures, Jump Crypto, Electric Capital, QCP Capital, Jane Street Capital, BH Digital, Flow Traders, and Belvedere Trading. Membrane Labs was founded by Carson Cook in 2019.
Spine BioPharma – $2.4M
Spine BioPharma, a non-surgical solution for back pain, has raised $2.4M in funding according to a recent SEC filing. The filing indicates that the total offering is for $15M, the transaction is structured as a convertible note, and there were three investors in this close. Founded by Marc R. Viscogliosi in 2015, Spine BioPharma has now raised a total of $38.3M in reported equity funding.
